Daniel P. O’Day is the Chairman and Chief Executive Officer of Gilead Sciences, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines in areas of unmet medical need. O’Day joined Gilead in March 2019, bringing with him extensive experience in the pharmaceutical industry. Prior to his role at Gilead, he spent nearly 30 years at Roche, where he held various leadership positions, including CEO of Roche Pharmaceuticals and member of the Corporate Executive Committee. During his tenure at Roche, O’Day played a pivotal role in the development and global expansion of the company's pharmaceutical division, overseeing the launch of several blockbuster drugs and significantly increasing the company’s revenue. As CEO of Gilead Sciences, O’Day has been instrumental in steering the company through a period of transformation and growth. Under his leadership, Gilead has expanded its research and development efforts, focusing on therapeutic areas such as virology, oncology, and inflammation. O’Day has also been a strong advocate for improving access to medicines, particularly in underserved communities, and has led initiatives to enhance Gilead’s global health programs. His strategic vision has helped Gilead strengthen its portfolio and position the company as a leader in the biopharmaceutical industry. In addition to his corporate responsibilities, O’Day is actively involved in various industry and community organizations. He serves on the board of directors for the Biotechnology Innovation Organization (BIO) and is a member of the Business Roundtable, where he contributes to discussions on healthcare policy and innovation. O’Day’s leadership and commitment to advancing medical science have earned him recognition within the industry, and he continues to drive Gilead Sciences forward in its mission to transform the lives of patients worldwide.